SEC INSIDER TRANSACTIONS

RESMED INC (RMD) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

RMD · RESMED INC

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 20 filings · fetched 2026-11-13T19:57:04Z

Recent reported activity

0purchase rows on this page

4sale rows on this page

36matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-08-07Filed 2026-08-11	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $202.410 - $204.160. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year. References: F1, F3	M Exercise / conversionResMed Common Stock Options · Derivative	4,991D	0	Direct	Form 4 ↗0000943819-26-000043
2026-08-07Filed 2026-08-11	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $202.410 - $204.160. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year. References: F1, F2	S Sale (market/private)ResMed Common Stock · Non-derivative	4,991D	205.6895	Direct	Form 4 ↗0000943819-26-000043
2026-08-07Filed 2026-08-11	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $202.410 - $204.160. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year. References: F1	M Exercise / conversionResMed Common Stock · Non-derivative	4,991A	146.34	Direct	Form 4 ↗0000943819-26-000043
2026-08-05Filed 2026-08-06	FARRELL PETER CDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. References: F1	S Sale (market/private)ResMed Common Stock · Non-derivative	8,000D	225	Direct	Form 4 ↗0000943819-26-000040
2026-07-07Filed 2026-07-09	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $216.772 - $219.700. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year. References: F1, F3	M Exercise / conversionResMed Common Stock Options · Derivative	4,991D	0	Direct	Form 4 ↗0000943819-26-000038
2026-07-07Filed 2026-07-09	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $216.772 - $219.700. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year. References: F1, F2	S Sale (market/private)ResMed Common Stock · Non-derivative	4,991D	218.5475	Direct	Form 4 ↗0000943819-26-000038
2026-07-07Filed 2026-07-09	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $216.772 - $219.700. The price reported above reflects the weighted average sale price. F3 Represents date options first become exercisable. Options vest 1/3 per year. References: F1	M Exercise / conversionResMed Common Stock · Non-derivative	4,991A	146.34	Direct	Form 4 ↗0000943819-26-000038
2026-06-08Filed 2026-06-09	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $192.605 - $194.715. The price reported above reflects the weighted average sale price. F3 Includes 32.671 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan. References:	M Exercise / conversionResMed Common Stock Options · Derivative	4,991D	0	Direct	Form 4 ↗0000943819-26-000035
2026-06-08Filed 2026-06-09	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $192.605 - $194.715. The price reported above reflects the weighted average sale price. F3 Includes 32.671 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan. References: F1, F2, F3	S Sale (market/private)ResMed Common Stock · Non-derivative	4,991D	193.962	Direct	Form 4 ↗0000943819-26-000035
2026-06-08Filed 2026-06-09	Farrell Michael J.Director · Officer · Chairman and CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 This transaction was executed in multiple trades at prices ranging from $192.605 - $194.715. The price reported above reflects the weighted average sale price. F3 Includes 32.671 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan. References: F1	M Exercise / conversionResMed Common Stock · Non-derivative	4,991A	146.34	Direct	Form 4 ↗0000943819-26-000035
2026-06-01Filed 2026-06-03	Rider Michael JOfficer · Global General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 06/01/2023. F2 Includes 66.0288 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan. References: F1, F2	F WithholdingResMed Common Stock · Non-derivative	268.742D	190.57	Direct	Form 4 ↗0000943819-26-000033

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.